Baricitinib for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 12, Issue 9, 2016, Pages 911-919

  Kubo, Satoshi ^a   Nakayamada, Shingo ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Baricitinib; efficacy; JAK; safety; small molecule; STAT

Indexed keywords

ADALIMUMAB; BARICITINIB; CREATINE KINASE; CREATININE; HIGH DENSITY LIPOPROTEIN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; METHOTREXATE; PLACEBO; PROTEIN KINASE TYK2; TRIACYLGLYCEROL; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; SULFONAMIDE;

ADVERSE OUTCOME; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; CLINICAL TRIALS AS TOPIC; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; SULFONAMIDES;

EID: 84982840474     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2016.1214576     Document Type: Article

References (51)

1. J.S.Smolen, D.Aletaha, J.W.Bijlsma, et al. Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis. 2010;69:631–637.
2. J.S.Smolen, F.C.Breedveld, G.R.Burmester, et al. Treating rheumatoid arthritis to target:2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
3. J.S.Smolen, D.Van Der Heijde, K.P.Machold, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73:3–5.
4. T.Hunter The age of crosstalk:phosphorylation, ubiquitination, and beyond. Mol Cell. 2007;28:730–738.
5. J.J.O’Shea, R.Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36:542–550.•• Overall review of the JAK–STAT pathway.
6. M.W.Karaman, S.Herrgard, D.K.Treiber, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127–132.
7. K.Ghoreschi, M.I.Jesson, X.Li, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011.
8. R.Fleischmann, J.Kremer, J.Cush, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
9. J.Kremer, Z.G.Li, S.Hall, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis:a randomized trial. Ann Intern Med. 2013;159:253–261.
10. D.Van Der Heijde, Y.Tanaka, R.Fleischmann, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate:12-month data from a 24-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.
11. R.F.Van Vollenhoven, R.Fleischmann, S.Cohen, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
12. G.R.Burmester, R.Blanco, C.Charles-Schoeman, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors:a randomised phase 3 trial. Lancet. 2013;381:451–460.
13. J.E.DarnellJr, I.M.Kerr, G.R.Stark. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–1421.
14. S.J.Rodig, M.A.Meraz, J.M.White, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373–383.
15. H.Neubauer, A.Cumano, M.Müller, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397–409.
16. S.Pelletier, S.Gingras, M.Funakoshi-Tago, et al. Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function. Mol Cell Biol. 2006;26:8527–8538.
17. C.James, V.Ugo, J.-P.LeCouédic, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.
18. W.J.Leonard, J.J.O’Shea. Jaks and STATs:biological implications. Annu Rev Immunol. 1998;16:293–322.
19. I.Firmbach-Kraft, M.Byers, T.Shows, et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene. 1990;5:1329–1336.
20. L.Velazquez, M.Fellous, G.R.Stark, et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992;70:313–322.
21. M.Karaghiosoff, H.Neubauer, C.Lassnig, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity. 2000;13:549–560.
22. Y.Minegishi, M.Saito, T.Morio, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745–755.
23. K.Maeshima, K.Yamaoka, S.Kubo, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64:1790–1798.
24. S.P.Wang, S.Iwata, S.Nakayamada, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014;73:2213–2215.
25. S.Kubo, K.Yamaoka, M.Kondo, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192–2198.
26. J.Fridman, P.Scherle, R.Collins, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis:preclinical characterization of INCB028050. J Immunol. 2010;184:5298–5307.
27. Public data sheet form Selleck Chem.com. Available from:http://www.selleckchem.com/datasheet/baricitinib-ly3009104-DataSheet.html
28. J.G.Shi, X.Chen, F.Lee, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54:1354–1361.
29. P.Emery, I.McInnes, M.Genovese et al. Characterization of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies. ACR/ARHP Annual Meeting; ABSTRACT NUMBER:1047; 2015 Nov 8; San Francisco
30. S.Kubo, S.Nakayamada, N.Nakano, et al. Baricitinib targets the type I IFN/STAT-mediated activities of human T cells and dendritic cells. EULAR congress; ABSTRACT NUMBER:THU0203; 2016; London
31. C.Payne, X.Zhang, N.Shahri, et al. Evaluation of potential drug-drug interactions with baricitinib. EULAR congress; ABSTRACT NUMBER:AB0492; 2015 Jun 11; Rome
32. E.C.Keystone, P.C.Taylor, E.Drescher, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74:333–340.
33. Y.Tanaka, K.Emoto, Z.Cai, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy:a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016;43:504–511.
34. D.T.Felson, J.J.Anderson, M.Boers, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–735.
35. M.C.Genovese, J.Kremer, O.Zamani, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243–1252.• First report of the phase III study for the treatment with baricitinib in patients with RA.
36. M.Dougados, D.Van Der Heijde, Y.-C.Chen et al. Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to CDMARD therapy:results of the phase 3 RA-BUILD study. EULAR congress; ABSTRACT NUMBER:LB0001; 2015 Jun 11; Rome
37. R.Fleischmann, T.Takeuchi, D.Schlichting et al. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs):phase 3 trial results. ACR/ARHP Annual Meeting; ABSTRACT NUMBER:1045; 2015 Nov 8; San Francisco
38. P.Taylor, E.Keystone, D.Van Der Heijde et al. Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy:results of a phase 3 study. ACR/ARHP Annual Meeting; ABSTRACT NUMBER:2L; 2015 Nov 10; San Francisco
39. D.Ummarino. Rheumatoid arthritis:RA-BEACON illuminates baricitinib. Nat Rev Rheumatol. 2016;12:313–313.
40. K.L.Winthrop, H.Yamanaka, H.Valdez, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–2684.
41. N.Nishimoto, K.Yoshizaki, N.Miyasaka, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody:a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–1769.
42. E.J.Jeyarajah, W.C.Cromwell, J.D.Otvos. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–870.
43. S.Mora, J.D.Otvos, N.Rifai, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931–939.
44. S.Parish, A.Offer, R.Clarke, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012;125:2469–2478.
45. J.M.Kremer, B.J.Bloom, F.C.Breedveld, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis:results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895–1905.
46. S.Y.Kawashiri, A.Kawakami, S.Yamasaki, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011;31:451–456.
47. N.Nishimoto, K.Yoshizaki, K.Maeda, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426–1435.
48. A.Souto, E.Salgado, J.R.Maneiro, et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials:a systematic review and meta-analysis. Arthrit Rheumatol (Hoboken, NJ). 2015;67:117–127.
49. V.P.Nell, K.P.Machold, G.Eberl, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906–914.
50. D.Aletaha, T.Neogi, A.J.Silman, et al. Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–1588.
51. D.Aletaha, T.Neogi, A.J.Silman, et al. Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581.